Cannabinoid receptor 2 (CB₂) agonists and antagonists: a patent update

References

• Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–564.
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–65.
   PubMed Web of Science ®Google Scholar
• Sawzdargo M, Nguyen T, Lee DK, et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res. 1999;64(2):193–198.
   PubMedGoogle Scholar
• Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc B Biol Sci. 2012;367(1607):3353–3363.
   PubMed Web of Science ®Google Scholar
• Picone RP, Kendall DA. Minireview: from the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation. Mol Endocrinol. 2015;29(6):801–813.
   PubMed Web of Science ®Google Scholar
• Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310:329–332.
   PubMed Web of Science ®Google Scholar
• Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry. 2016;79:516–525.
   PubMed Web of Science ®Google Scholar
• Dhopeshwarkar A, Mackie K. CB2 cannabinoid receptors as a therapeutic target - what does the future hold? Mol Pharmacol. 2014;86:430–437.
   PubMed Web of Science ®Google Scholar
• Han S, Chen JJ, Chen JZ. Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor. Mini Rev Med Chem. 2014;14(5):426–443.
   PubMed Web of Science ®Google Scholar
• Han S, Thatte J, Buzard DJ, et al. Therapeutic utility of cannabinoid receptor type 2 (CB2) selective agonists. J Med Chem. 2013;56(21):8224–8256.
   PubMed Web of Science ®Google Scholar
• Murineddu G, Deligia F, Dore A, et al. Different classes of CB2 ligands potentially useful in the treatment of pain. Recent Pat CNS Drug Discov. 2013;8(1):42–69.
   PubMedGoogle Scholar
• Gilron I, Dickenson AH. Emerging drugs for neuropathic pain. Expert Opin Emerg Drugs. 2014;19(3):329–341.
   PubMed Web of Science ®Google Scholar
• Doan L, Manders T, Wang J. Neuroplasticity underlying the comorbidity of pain and depression. Neural Plast. 2015;2015:504691.
   PubMedGoogle Scholar
• Whyte LS, Ford L, Ridge SA, et al. Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. Br J Pharmacol. 2012;165(8):2584–2597.
   PubMed Web of Science ®Google Scholar
• Rossi F, Bellini G, Tortora C, et al. CB2 and TRPV1 receptors oppositely modulate in vitro human osteoblast activity. Pharmacol Res. 2015;99:194–201.
   PubMed Web of Science ®Google Scholar
• Smith M, Wilson R, O’Brien S, et al. The effects of the endocannabinoids anandamide and 2-arachidonoylglycerol on human osteoblast proliferation and differentiation. PLoS One. 2015;10:1–15.
   Google Scholar
• Staunton CA, Mobasheri A, Barrett-Jolley R. High hopes for cannabinoid agonists in the treatment of rheumatic diseases. BMC Musculoskelet Disord. 2014;15(1):1–5.
   PubMed Web of Science ®Google Scholar
• Gamaleddin IH, Trigo JM, Gueye AB, et al. Role of the endogenous cannabinoid system in nicotine addiction: novel insights. Front Psychiatry. 2015;6:1–12.
   PubMed Web of Science ®Google Scholar
• Madhavan PN, Figueroa G, Casteleiro G, et al. Alcohol versus cannabinoids: a review of their opposite neuro-immunomodulatory effects and future therapeutic potentials. J Alcohol Drug Depend. 2015;03(01):1–17.
   Google Scholar
• Parsons LH, Hurd YL. Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci. 2015;16:579–594.
   PubMed Web of Science ®Google Scholar
• Verty ANA, Stefanidis A, McAinch AJ, et al. Anti-obesity effect of the CB2 receptor agonist JWH-015 in diet-induced obese mice. PLoS One. 2015;10(11):e0140592.
   PubMed Web of Science ®Google Scholar
• Bermudez-Silva FJ, Sanchez-Vera I, Suarez J, et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol. 2007;565(1–3):207–211.
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz J, Moro MA, Martínez-Orgado J. Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics. 2015;12(4):793–806.
   PubMed Web of Science ®Google Scholar
• Gómez-Gálvez Y, Palomo-Garo C, Fernández-Ruiz J, et al. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:200–208.
   PubMed Web of Science ®Google Scholar
• Javid FA, Phillips RM, Afshinjavid S, et al. Cannabinoid pharmacology in cancer research: A new hope for cancer patients? Eur J Pharmacol. 2016;775:1–14.
   PubMed Web of Science ®Google Scholar
• Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436–444.
   PubMed Web of Science ®Google Scholar
• Morales P, Blasco-Benito S, Andradas C, et al. A selective, non-toxic CB2 cannabinoid o-quinone with in vivo activity against triple negative breast cancer. J Med Chem. 2015;58(5):2256–2264.
   PubMed Web of Science ®Google Scholar
• Molina PE, Winsauer P, Zhang P, et al. Cannabinoid administration attenuates the progression of simian immunodeficiency virus. AIDS Res Hum Retroviruses. 2011;27(6):585–592.
   PubMed Web of Science ®Google Scholar
• Robinson RH, Meissler JJ, Fan X, et al. A CB2-selective cannabinoid suppresses T-cell activities and increases Tregs and IL-10. J Neuroimmune Pharmacol. 2015;10:318–332.
   PubMed Web of Science ®Google Scholar
• Riether D. Selective cannabinoid receptor 2 modulators: a patent review 2009–present. Expert Opin Ther Pat. 2012;22(5):495–510.
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche AG Pyrazine-2-carboxamide derivatives. WO2008040649A2 (2008)
   Google Scholar
• Hoffmann-La Roche AG. Pyridin-2-amides useful as CB2 agonists. WO2012168350A1. 2012.
   Google Scholar
• Hoffmann-La Roche AG. Pyridine-2-amides useful as CB2 Agonists. WO2014086805. 2014
   Google Scholar
• Hoffmann-La Roche AG. Novel pyridine derivatives. WO2014154612A1. 2014.
   Google Scholar
• Hoffmann-La Roche AG Novel pyridine derivatives. WO2014086705A1. 2014.
   Google Scholar
• Hoffmann-La Roche AG. Pyridine-2-amides useful as CB2 Agonists. WO2014086806A1. 2014
   Google Scholar
• Hoffmann-La Roche AG. 5,6-Disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists. WO2015150438A1. 2015.
   Google Scholar
• Hoffmann-La Roche AG. Pyridine-2-amides useful as cb2 agonists. WO2015150440. 2015.
   Google Scholar
• Slavik R, Grether U, Müller Herde A, et al. Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor. J Med Chem. 2015;58(10):4266–4277.
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche AG. Novel Pyrazine Derivatives. WO2013060751A1. 2013.
   Google Scholar
• Hoffmann-La Roche AG. Novel Pyrazine Derivatives as CB2 Receptor Agonists. WO2014086807A1. 2014.
   Google Scholar
• Hoffmann-La Roche AG. [1,2,3]-triazolo[4,5-d]pyrimidine derivatives as cannabinoid receptor 2 agonists. WO2013076182A1. 2013.
   Google Scholar
• Hoffmann-La Roche AG Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives. US2013116236A1. 2013.
   Google Scholar
• Hoffmann-La Roche AG. Pyrrolo[2,3-d]pyrimidine derivatives as CB2 receptor agonists. WO2014177527A1. 2014.
   Google Scholar
• Hoffmann-La Roche AG. Novel pyrazole derivatives as CB2 agonists. WO2014135507A1. 2014.
   Google Scholar
• Hoffmann-La Roche AG. Purine derivatives as CB2 receptor agonists. WO2014177490A1. 2014.
   Google Scholar
• Nettekoven M, Adam JM, Bendels S, et al. Novel triazolopyrimidine-derived cannabinoid receptor 2 agonists as potential treatment for inflammatory kidney diseases. ChemMedChem. 2016;11(2):179–189.
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche AG. Novel adamantylderivatives as cannabinoid receptor 2 agonists. WO2014005968A1. 2014.
   Google Scholar
• Hoffmann-La Roche AG. Novel Tetrazolone Derivatives. WO2014198592A1. 2014.
   Google Scholar
• Nettekoven M, Fingerle J, Grether U, et al. Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening. Bioorg Med Chem Lett. 2013;23(5):1177–1181.
   PubMed Web of Science ®Google Scholar
• Rossi F, Bellini G, Nobili B, et al. Association of the cannabinoid receptor 2 (CB2) Gln63Arg polymorphism with indices of liver damage in obese children: an alternative way to highlight the CB2 hepatoprotective properties. Hepatology. 2011;54(3):1102–1103.
   PubMed Web of Science ®Google Scholar
• Rossi F, Bellini G, Tolone C, et al. The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention. Pharmacol Res. 2012;66(1):88–94.
   PubMed Web of Science ®Google Scholar
• Ishiguro H, Horiuchi Y, Ishikawa M, et al. Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry. 2010;67(10):974–982.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH. Sulfonyl Compounds which Modulate de CB2 Receptor. WO2012012307A1. 2012.
   Google Scholar
• Boehringer Ingelheim International GmbH. Novel Cyanodimethylmethyl-isoxazoles and -[1,3,4]thiadiazoles. WO2014184327. 2014.
   Google Scholar
• Yrjölä S, Kalliokoski T, Navia-Paldanius, et al. Ligand-based virtual screening for cannabinoid ligands. In: 21st Annual symposium of the International Cannabinoid Research Society; 2011 July 5–10; St Charles, IL.
   Google Scholar
• Sanofi. 1,3,5-Triazine-2-Amine derivatives, preparation thereof and diagnostic and therapeutic use thereof. WO2013087643A1. 2013.
   Google Scholar
• Hortala L, Arnaud J, Roux P, et al. Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor. Bioorganic Med Chem Lett. 2014;24(1):283–287.
   PubMed Web of Science ®Google Scholar
• Arena Pharmaceuticals. Crystalline forms and processes for the preparation of condensed diazacyclopropa[a]pentalene as cannabinoid receptor modulators. WO2012116276A1. 2012.
   Google Scholar
• Arena Pharmaceuticals. Cannabinoid Receptor Modulators. WO2012116278A1. 2012.
   Google Scholar
• Arena Pharmaceuticals. Cannabinoid Receptor Modulators. WO2012116277A1. 2012.
   Google Scholar
• Arena Pharmaceuticals. Cannabinoid Receptor Modulators. WO2012116279A1. 2012.
   Google Scholar
• Lupin Limited. Cannabinoid Receptor Modulators. WO2012090177A2. 2012.
   Google Scholar
• Lupin Limited. Isoquinoline Derivatives for use as Cannabinoid Receptor Modulators. WO2012090179A2. 2012.
   Google Scholar
• Lupin Limited. Cannabinoid Receptor Modulators. WO2013005168A2. 2013.
   Google Scholar
• ISIS Innovation Limited. Cannabinoid-2-Receptor Agonists. WO2013041859A1. 2013.
   Google Scholar
• Gianella-Borradori M, Christou I, Bataille CJR, et al. Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists. Bioorganic Med Chem. 2015;23(1):241–263.
   PubMed Web of Science ®Google Scholar
• Bayer Pharma. CB2 for the Treatment and Prevention of Endometriosis. WO2012098090A1. 2012.
   Google Scholar
• Cannabis RE. Treatments in obstetrics and gynecology: a historical review. J Cannabis Ther. 2002;2(3–4):5–35.
   Google Scholar
• Costa MA, Keating E, Fonseca BM, et al. Arachidonoylglycerol impairs human cytotrophoblast cells syncytialization: influence of endocannabinoid signalling in placental development. Mol Cell Endocrinol. 2015;339:386–394.
   Web of Science ®Google Scholar
• Dimitrieva N, Nagabukuro H, Resuehr D, et al. Endocannabinoid involvement in endometriosis. Pain. 2010;151(3):703–710.
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Inc. Fused ring pyridine compound. US2013143874A1. 2013.
   Google Scholar
• Colosseum Combinatorial Chemistry Centre for Technology. Compound of 2,3-Dihydro-4H-1,3-Benzoxazine-4-one, method for preparing them and pharmaceutical form comprising them. WO2014097188. 2014.
   Google Scholar
• Proteimax Biotecnologia. Modified peptide, CB receptor ligand, Kit, in vitro process for evaluating CB receptor bonds, uses, pharmaceutical composition for modulating CB receptor activity. WO2014008567. 2014.
   Google Scholar
• Ariel University Research and Development Company Ltd. Treatment of schizophrenia using beta-caryophyllene and CB2 receptor agonists. WO2013140342A1. 2013.
   Google Scholar
• Ariel University Research and Development Company Ltd. CB2 receptor ligands for the treatment of psychiatric disorders. WO2014170902A1. 2014.
   Google Scholar
• INSERM. Derivatives of 2H-pyrazolo[4,3-c]quinolin-3(5h)-one and use thereof. WO2015189523A1. 2015.
   Google Scholar
• Lynch M, Kelly M. Compositions and methods for treatment of ocular inflammation and pain. WO2015074137A1. 2015.
   Google Scholar
• University of Montana. Novel tricyclic modulators of cannabinoid receptors. US2012039804A1. 2012.
   Google Scholar
• Costantino CM, Gupta A, Yewdall AW, et al. Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PLoS One. 2012;7(3):e33961.
   PubMed Web of Science ®Google Scholar
• Travis CR Method for treatment of HIV and diseases of immune dysregulation. US20120122917. 2012.
   Google Scholar
• Temple University. Cannabinoid receptor treatment. WO2013025984A2. 2013.
   Google Scholar
• Consejo Superior de Investigaciones Cinetificas. Novel chromene quinones for modulating cannabinoid receptors CB2 having antitumor activity. WO2015140377. 2015.
   Google Scholar
• Morales P, Vara D, Goméz-Cañas M, et al. Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity. Eur J Med Chem. 2013;70:111–119.
   PubMed Web of Science ®Google Scholar
• Consejo Superior de Investigaciones Cinetificas. Chromenopyrazolediones as cannabinoid quinone derivatives having anti-tumour activity. WO2014013117. 2014.
   Google Scholar
• Sutter West Bay Hospitals. Cannabidinoid derivatives as therapeutic agents. US20130209483A1. 2013.
   Google Scholar
• ETH Zürich. Preparation of 4-oxo-1,4-dihydroquinoline-3-carboxamides as selective ligands for cannabinoid receptor 2 for diagnosis and therapy. WO 2016005419A1/EP 2966062A1. 2016.
   Google Scholar
• University of Pittsburgh. Novel CB2 inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases. US2013172388A1. 2013.
   Google Scholar
• Diaz P, Phatak SS, Xu J, et al. 2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling. ChemMedChem. 2009;4(10):1615–1629.
   PubMed Web of Science ®Google Scholar
• Northeastern University. Novel cannabinergic compounds and uses thereof. WO2014039042A1. 2014.
   Google Scholar
• Northeastern University. 2-Cycloalkyl-Resorcinol Compounds as Cannabinergic Ligands. WO2014062965. 2014.
   Google Scholar
• Northeastern University. Cannabinergic Nitrate Esters and Related Analogs. WO2014134127A1. 2014.
   Google Scholar
• Sardinha J, Lehmann C, Kelly M. Targeting the endocannabinoid system to treat sepsis. Signa Vitae. 2013;8:9–14.
   Web of Science ®Google Scholar
• [cited 2016 May 4]. Available from https://clinicaltrials.gov.
   Google Scholar
• Morales P, Goya P, Jagerovic N, et al. Allosteric modulators of the CB 1 cannabinoid receptor : a structural update review. Cannabis Cannabinoid Res. 2016;1(1):22–30.
   PubMedGoogle Scholar
• Khajehali E, Malone DT, Glass M, et al. Biased agonism and biased allosteric modulation at the CB 1 cannabinoid receptors. Mol Pharmacol. 2015;88:368–379.
   PubMed Web of Science ®Google Scholar
• Glass M, Govindpani K, Furkert DP, et al. One for the price of two … are bivalent ligands targeting cannabinoid receptor dimers capable of simultaneously binding to both receptors? Trends Pharmacol Sci. 2016. doi:10.1016/j.tips.2016.01.010.
   PubMed Web of Science ®Google Scholar
• Nimczick M, Decker M. New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds. ChemMedChem. 2015;10(5):773–786.
   PubMed Web of Science ®Google Scholar
• Callén L, Moreno E, Barroso-Chinea P, et al. Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem. 2012;287:20851–20865.
   PubMed Web of Science ®Google Scholar
• Balenga NA, Martínez-Pinilla E, Kargl J, et al. Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signaling. Br J Pharmacol. 2014;171:5387–5406.
   PubMed Web of Science ®Google Scholar
• Moreno E, Andradas C, Medrano M, et al. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J Biol Chem. 2014;289:21960–21972.
   PubMed Web of Science ®Google Scholar